Cargando…

Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma

Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate programmed cell death (apoptosis), defects i...

Descripción completa

Detalles Bibliográficos
Autor principal: Fulda, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263644/
https://www.ncbi.nlm.nih.gov/pubmed/22294874
http://dx.doi.org/10.1155/2012/326210
_version_ 1782221902615412736
author Fulda, Simone
author_facet Fulda, Simone
author_sort Fulda, Simone
collection PubMed
description Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate programmed cell death (apoptosis), defects in apoptosis programs in cancer cells may result in resistance. Evasion of apoptosis in rhabdomyosarcoma may be caused by defects in the expression or function of critical mediators of apoptosis or in aberrant expression of antiapoptotic proteins. Therefore, the identification of the molecular mechanisms that confer primary or acquired resistance to apoptosis in rhabdomyosarcoma presents a critical step for the rational development of molecular targeted drugs. This approach will likely open novel perspectives for the treatment of rhabdomyosarcoma.
format Online
Article
Text
id pubmed-3263644
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32636442012-01-31 Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma Fulda, Simone Sarcoma Review Article Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate programmed cell death (apoptosis), defects in apoptosis programs in cancer cells may result in resistance. Evasion of apoptosis in rhabdomyosarcoma may be caused by defects in the expression or function of critical mediators of apoptosis or in aberrant expression of antiapoptotic proteins. Therefore, the identification of the molecular mechanisms that confer primary or acquired resistance to apoptosis in rhabdomyosarcoma presents a critical step for the rational development of molecular targeted drugs. This approach will likely open novel perspectives for the treatment of rhabdomyosarcoma. Hindawi Publishing Corporation 2012 2012-01-12 /pmc/articles/PMC3263644/ /pubmed/22294874 http://dx.doi.org/10.1155/2012/326210 Text en Copyright © 2012 Simone Fulda. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Fulda, Simone
Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
title Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
title_full Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
title_fullStr Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
title_full_unstemmed Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
title_short Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
title_sort cell death pathways as therapeutic targets in rhabdomyosarcoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263644/
https://www.ncbi.nlm.nih.gov/pubmed/22294874
http://dx.doi.org/10.1155/2012/326210
work_keys_str_mv AT fuldasimone celldeathpathwaysastherapeutictargetsinrhabdomyosarcoma